Clinical Trials Sponsored by BioCan Rx

Total 1020 results

Biogen

Withdrawn

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-2)

Trigeminal Neuralgia
Biogen

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Biogen

Completed

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteer

United States
Biogen

Completed

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Healthy Volunteer

United States
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
Biogen

Completed

Study of BIIB091 Formulations in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

A Study to Assess Choroideremia (CHM) Health Outcomes

Choroideremia

United States
Biogen

Terminated

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)

Cognitive Dysfunction | Alzheimer's Disease

United States
Biogen

Completed

Natural Disease Progression in Participants With Choroideremia

Choroideremia

United States
Biogen

Completed

Tecfidera and the Gut Microbiota (TECONGUT)

Multiple Sclerosis, Relapsing-Remitting

Norway
Biogen

Terminated

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

Alzheimer's Disease

United States, Spain, Belgium, Switzerland, Poland, Canada, Italy, Germany, Netherlands, Sweden, France, Japan, Finland
Biogen

Completed

Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers

Stroke | Traumatic Brain Injury

United States
Biogen

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Parkinson's Disease

Japan
Biogen

Completed

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States
Biogen

Withdrawn

Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy

Diabetic Neuropathies | Healthy Volunteers
Biogen

Completed

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

Healthy Adult Subjects | Healthy Elderly Subjects

United States
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Spinal Muscular Atrophy

United States
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Biogen

Terminated

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis (SPIRIT)

Idiopathic Pulmonary Fibrosis

United States, Italy, Belgium, Czechia, Russian Federation, Korea, Republic of, Australia, France, Israel, Spain, Poland, Netherlands, Denmark, Greece, Argentina, Chile, United Kingdom
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Healthy Volunteer | Alzheimer's Disease

United States
Biogen

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Healthy

United States
Biogen

Completed

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Multiple Sclerosis

United States
Biogen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Hearing Loss, Sensorineural

United States
Biogen

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Biogen

Completed

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

Scan-Rescan Sub-Study of MS PATHS

Multiple Sclerosis

United States
Biogen

Completed

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Healthy | Parkinson's Disease

United States
Biogen

Completed

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey
Biogen

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

Healthy Volunteer

United Kingdom
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

Fatigue | Relapsing-Remitting Multiple Sclerosis

Sweden, Norway, Austria, Denmark
Biogen

Completed

Benepali® PEN Patient Satisfaction Survey

Rheumatoid Arthritis | Spondyloarthropathies

Germany
Biogen

Completed

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (PROTYS)

Multiple Sclerosis

Switzerland
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

Healthy Subjects

United States
Biogen

Completed

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy (VITALITY)

Relapsing-Remitting Multiple Sclerosis

Italy
Biogen

Completed

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Relapsing Remitting Multiple Sclerosis

Germany
Biogen

Completed

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Healthy Volunteers

United States
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

Bipolar Disorder | Bipolar Depression

United Kingdom
Biogen

Completed

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Healthy Volunteers

United States
Biogen

Completed

Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

Healthy

United Kingdom
Biogen

Completed

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

Healthy Volunteer

United States
Biogen

Completed

Study of Utilization Patterns of Dimethyl Fumarate in Germany

Multiple Sclerosis

Germany
Biogen

Terminated

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)

Multiple Sclerosis, Secondary Progressive

United States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
Biogen

Terminated

Single Ascending Doses of BIIB063 in Healthy Volunteers

Healthy

United Kingdom
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Biogen

Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (EXPLORE)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States

3

Subscribe